Apr 15, 2019 6:00am EDT Lexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services
Apr 09, 2019 5:55am EDT Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options
Feb 26, 2019 6:15am EST Lexaria Bioscience Comments on FDA Statement on Novel Nicotine Replacement Therapies
Feb 21, 2019 6:15am EST Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria's DehydraTECH(TM) Powered TurboCBD(TM) Capsules
Jan 17, 2019 8:30am EST Altria Group Invests Up to $12M in Lexaria Bioscience’s DehydraTECH™ Technology
Jan 15, 2019 11:39am EST Lexaria Bioscience Announces Partnership with Altria to Fund Research and Development of DehydraTECH(TM) Technology for Oral Nicotine
Nov 26, 2018 6:30am EST Lexaria Bioscience Submits Application to Health Canada for Research License and Appoints Chief Legal Officer
